Pro: Aprotinin Should Be Used in Coronary Artery Bypass Graft Surgery With Cardiopulmonary Bypass

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 21, Issue 2, 2007, Pages 298-301

  Hill, Steven E ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

acute; aprotinin; blood transfusion; cerebrovascular accident; coronary artery bypass grafting; renal insufficiency

Indexed keywords

AMINOCAPROIC ACID; AMINOGLYCOSIDE; APROTININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LYSINE DERIVATIVE; SERINE PROTEINASE INHIBITOR; TRANEXAMIC ACID;

ARTICLE; BLEEDING; BLOOD TRANSFUSION; BRAIN DISEASE; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CRITICALLY ILL PATIENT; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HEART SURGERY; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; LEGAL ASPECT; MEDICAL DECISION MAKING; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; STROKE; SURVIVAL; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 34047161072     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jvca.2006.11.009     Document Type: Note

References (22)

1. Cosgrove D.M.3r., Heric B., Lytle B.W., et al. Aprotinin therapy for reoperative myocardial revascularization: A placebo-controlled study. Ann Thorac Surg 54 (1992) 1031-1036 discussion 1036-1038
2. Lemmer Jr. J.H., Stanford W., Bonney S.L., et al. Aprotinin for coronary bypass operations: Efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg 107 (1994) 543-551 discussion 551-543
3. Levy J.H., Pifarre R., Schaff H.V., et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 92 (1995) 2236-2244
4. Lemmer Jr. J.H., Dilling E.W., Morton J.R., et al. Aprotinin for primary coronary artery bypass grafting: A multicenter trial of three dose regimens. Ann Thorac Surg 62 (1996) 1659-1667 discussion 1667-1658
5. Alderman E.L., Levy J.H., Rich J.B., et al. Analyses of coronary graft patency after aprotinin use: Results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg 116 (1998) 716-730
6. Mangano D.T., Tudor I.C., and Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 354 (2006) 353-365
7. USFDA. Cardiovascular and renal drugs advisory committee meeting (2006). http://www.fda.gov/ohrms/dockets/ac/cder06.html/minutes/2006-4234m-FinalMinutes.pdf Available at: www.fda.gov/ohrms/dockets/ac/cder06.html/minutes/2006-4234m-FinalMinutes.pdf. Accessed September 21
8. USFDA. FDA statement regarding new Trasylol data (2006). http://www.fda.gov/bbs/topics/news/2006/new01472.html Available at: www.fda.gov/bbs/topics/news/2006/new01472.html. Accessed September 29
9. USFDA. Aprotinin injection (marked as Trasylol) information (2006). http://www.fda.gov/cder/drug/infopage/aprotinin/default.htm Available at: www.fda.gov/cder/drug/infopage/aprotinin/default.htm. Accessed December 28
10. Sedrakyan A., Treasure T., and Elefteriades J.A. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 128 (2004) 442-448
11. Fremes S.E., Wong B.I., Lee E., et al. Meta-analysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg 58 (1994) 1580-1588
12. Laupacis A., and Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery: Meta-analyses using perioperative blood transfusion as the outcome. The International Study of Perioperative Transfusion (ISPOT) Investigators. Anesth Analg 85 (1997) 1258-1267
13. Munoz J.J., Birkmeyer N.J., Birkmeyer J.D., et al. Is epsilon-aminocaproic acid as effective as aprotinin in reducing bleeding with cardiac surgery?. A meta-analysis. Circulation 99 (1999) 81-89
14. Levi M., Cromheecke M.E., de Jonge E., et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: A meta-analysis of clinically relevant endpoints [see comments]. Lancet 354 (1999) 1940-1947
15. Karkouti K., Beattie W.S., Dattilo K.M., et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion 46 (2006) 327-338
16. Fauli A., Gomar C., Campistol J.M., et al. Kidney-specific proteins in patients receiving aprotinin at high- and low-dose regimens during coronary artery bypass graft with cardiopulmonary bypass. Eur J Anaesthesiol 22 (2005) 666-671
17. Brown J.R., Birkmeyer N.J., and O'Connor G.T. Aprotinin in cardiac surgery. N Engl J Med 354 (2006) 1953-1957 author reply 1953-1957
18. Hebert P.C., Wells G., Blajchman M.A., et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 340 (1999) 409-417
19. Koch C.G., Li L., Duncan A.I., et al. Transfusion in coronary artery bypass grafting is associated with reduced long-term survival. Ann Thorac Surg 81 (2006) 1650-1657
20. Engoren M.C., Habib R.H., Zacharias A., et al. Effect of blood transfusion on long-term survival after cardiac operation. Ann Thorac Surg 74 (2002) 1180-1186
21. Frumento R.J., O'Malley C.M., and Bennett-Guerrero E. Stroke after cardiac surgery: A retrospective analysis of the effect of aprotinin dosing regimens. Ann Thorac Surg 75 (2003) 479-483 discussion 483-474
22. Harmon D.C., Ghori K.G., Eustace N.P., et al. Aprotinin decreases the incidence of cognitive deficit following CABG and cardiopulmonary bypass: A pilot randomized controlled study. Can J Anaesth 51 (2004) 1002-1009